Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A
Cancers (Basel). 2025; 16(24.
PMID: 39766086
PMC: 11674514.
DOI: 10.3390/cancers16244187.
Mukhopadhyay S, Swan K, Pridjian G, Kolls J, Zhuang Y, Yin Q
Pathogens. 2024; 13(9).
PMID: 39338937
PMC: 11434807.
DOI: 10.3390/pathogens13090747.
Ben-Mordechai T, Lawrence Y, Symon Z, Shimoni-Sebag A, Amit U
Cancers (Basel). 2023; 15(22).
PMID: 38001732
PMC: 10669975.
DOI: 10.3390/cancers15225472.
Kim B
Front Immunol. 2023; 14:1167972.
PMID: 37153539
PMC: 10157096.
DOI: 10.3389/fimmu.2023.1167972.
Bashiri H, Tabatabaeian H
Int J Mol Sci. 2023; 24(7).
PMID: 37046991
PMC: 10094562.
DOI: 10.3390/ijms24076019.
Mechanisms of venetoclax resistance and solutions.
Liu J, Chen Y, Yu L, Yang L
Front Oncol. 2022; 12:1005659.
PMID: 36313732
PMC: 9597307.
DOI: 10.3389/fonc.2022.1005659.
Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.
Sklavenitis-Pistofidis R, Getz G, Ghobrial I, Papaioannou M
Front Oncol. 2022; 12:961421.
PMID: 35912171
PMC: 9331166.
DOI: 10.3389/fonc.2022.961421.
Pathogenic signaling in multiple myeloma.
Bolomsky A, Young R
Semin Oncol. 2022; 49(1):27-40.
PMID: 35125242
PMC: 9149055.
DOI: 10.1053/j.seminoncol.2022.01.005.
Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation.
Wang A, Qiu R, Zhang D, Zhao X
Transl Oncol. 2021; 15(1):101288.
PMID: 34847421
PMC: 8633684.
DOI: 10.1016/j.tranon.2021.101288.
Multipeptide stimulated PBMCs generate T/T for adoptive cell therapy in multiple myeloma.
Vardam-Kaur T, Pathangey L, McCormick D, Bergsagel P, Cohen P, Gendler S
Oncotarget. 2021; 12(20):2051-2067.
PMID: 34611479
PMC: 8487724.
DOI: 10.18632/oncotarget.28067.
A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment.
Qiu R, Murata S, Cheng C, Mori A, Nie Y, Mikami S
Cancers (Basel). 2021; 13(16).
PMID: 34439154
PMC: 8394300.
DOI: 10.3390/cancers13163997.
Extract Activates Growth and Survival Signal Transduction Networks to Stimulate Proliferation of Human Keratinocyte.
Nimlamool W, Potikanond S, Ruttanapattanakul J, Wikan N, Okonogi S, Jantrapirom S
Biology (Basel). 2021; 10(4).
PMID: 33916174
PMC: 8067174.
DOI: 10.3390/biology10040289.
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Algarin E, Quwaider D, Campos-Laborie F, Diaz-Tejedor A, Mogollon P, Vuelta E
Cells. 2021; 10(3).
PMID: 33806619
PMC: 8001939.
DOI: 10.3390/cells10030559.
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma.
Gupta V, Ackley J, Kaufman J, Boise L
Blood Lymphat Cancer. 2021; 11:11-24.
PMID: 33737856
PMC: 7965688.
DOI: 10.2147/BLCTT.S245191.
AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.
Bloedjes T, de Wilde G, Maas C, Eldering E, Bende R, van Noesel C
Blood Adv. 2020; 4(17):4151-4164.
PMID: 32898245
PMC: 7479958.
DOI: 10.1182/bloodadvances.2019001393.
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah P, Brandon A, Macleod K, Carragher N, Kirkin V, Kaiser M
BMC Cancer. 2020; 20(1):269.
PMID: 32228485
PMC: 7106683.
DOI: 10.1186/s12885-020-06735-2.
Multiple Myeloma: Available Therapies and Causes of Drug Resistance.
Pinto V, Bergantim R, Caires H, Seca H, Guimaraes J, Vasconcelos M
Cancers (Basel). 2020; 12(2).
PMID: 32050631
PMC: 7072128.
DOI: 10.3390/cancers12020407.
Extract Inhibits STAT3 Activation and Interleukin-6 Production in HeLa Cervical Cancer Cells.
Suradej B, Sookkhee S, Panyakaew J, Mungkornasawakul P, Wikan N, Smith D
Int J Mol Sci. 2019; 20(17).
PMID: 31470515
PMC: 6747281.
DOI: 10.3390/ijms20174226.
STAT3: A Promising Therapeutic Target in Multiple Myeloma.
Chong P, Chng W, De Mel S
Cancers (Basel). 2019; 11(5).
PMID: 31130718
PMC: 6562880.
DOI: 10.3390/cancers11050731.
Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma.
Slomp A, Peperzak V
Front Oncol. 2018; 8:533.
PMID: 30524962
PMC: 6256118.
DOI: 10.3389/fonc.2018.00533.